Complete Omis Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, today announced a major milestone with the successful achievement of Clinical Laboratory Improvement Amendments (CLIA) certification and College…
World-Leading VC Qiming Venture Partners Invests in Complete Omics to Accelerate Clinical Proteomics
Complete Omics Inc., a clinical proteomics and multi-omics technology company, announced the successful completion of its Series A financing, exclusively led by Qiming Venture Partners. The investment represents a major…
Complete Omics Inc. is pleased to share that our founder and CEO, Dr. Qing Wang, has been featured on the official website of the Wharton School of the University of Pennsylvania,…
January 29, 2022
Complete Omics Inc. announces its critical role in a landmark Science Advances publication identifying human endogenous retrovirus (HERV)–derived neoantigens as a new, scalable class of cancer immunotherapy targets.
From…
May 19, 2021
Complete Omics today highlighted a decade-long scientific journey in clinical proteomics, marking ten years since the landmark 2011 publication in Proceedings of the National Academy of Sciences (PNAS) that first demonstrated…
Sed ut perspiciatis, unde omnis iste natus error sit voluptatem accus
March 31, 2021
Complete Omics today underscores a defining moment in precision immunotherapy: foundational neoantigen-targeting breakthroughs published in Science and Science Immunology validate one of the core scientific theses upon which the company was…
October 31, 2019
Complete Omics announces that its founder and CEO, Dr. Qing Wang, led and designed a pioneering mass spectrometry method for the direct detection of cancer neoantigens at the…
October 10, 2019
Complete Omics today officially announces its founding with a bold and long-term mission:
To establish clinical proteomics as the next foundational pillar of precision medicine.
Over the…